[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.200.4. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

July 2019 - April 2015

Decade

Year

Issue

May 2018, Vol 4, No. 5, Pages 605-755

Original Investigation

Treatment Trends and Outcomes for Patients With Lymph Node–Positive Cancer of the Penis

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):643-649. doi:10.1001/jamaoncol.2017.5608

This National Cancer Database study reports and analyzes the practices and temporal trends for the use of lymph node dissection, chemotherapy, and radiotherapy from 2004 through 2014 for patients with advanced squamous cell carcinoma of the penis.

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2018;4(5):652-659. doi:10.1001/jamaoncol.2017.5818

This phase 3 randomized clinical trial compares the efficacy and safety of Janus kinase 2 inhibitor pacritinib with that of best available therapy, including ruxolitinib, in patients with myelofibrosis and thrombocytopenia.

Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):661-669. doi:10.1001/jamaoncol.2017.5847

This randomized clinical trial evaluates the efficacy and safety of transarterial chemoembolization plus external beam radiotherapy compared with sorafenib in patients with hepatocellular carcinoma and macroscopic vascular invasion.

Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):671-677. doi:10.1001/jamaoncol.2017.5431

This secondary analysis of data from the the FAP Erlotinib-Sulindac Trial (FAPEST) trial examines the effect of sulindac and erlotinib on colorectal adenoma formation and regression in patients with familial adenomatous polyposis.

A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):678-685. doi:10.1001/jamaoncol.2017.5667

This cohort study examines whether a magnetic resonance imaging–based prediction model can reduce unnecessary biopsies in patients with suspected prostate cancer.

Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers

Abstract Full Text
free access has active quiz
JAMA Oncol. 2018;4(5):686-693. doi:10.1001/jamaoncol.2017.5674

This cohort study evaluates the prevalence of domain-specific cognitive impairment and its association with overall survival among older patients with blood cancer.

Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2018;4(5):694-701. doi:10.1001/jamaoncol.2017.5808

This phase 3 randomized clinical trial uses prespecified sensitivity analyses from 1717 men with chemotherapy-naive metastatic castration-resistant prostate cancer to assess the clinical relevance of the Prostate Cancer Working Group 2 definition of radiographic progression-free survival.

Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(5):e175230. doi:10.1001/jamaoncol.2017.5230

This multi-institutional cohort study compares adjuvant radiotherapy with early-salvage radiotherapy used to manage postoperative patients with prostate cancer who have adverse pathological features.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

Abstract Full Text
open access online only
JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.0013

This single cohort study evaluates the safety and efficacy of pembrolizumab in patients with previously treated advanced gastric or gastroesophageal junction cancer.

Brief Report

Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study

Abstract Full Text
open access
JAMA Oncol. 2018;4(5):702-706. doi:10.1001/jamaoncol.2017.3361

This safety study investigates seizure rates in men at increased risk for seizure who are taking enzalutamide for metastatic castration-resistant prostate cancer.

“Job Lock” Among Long-term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):707-711. doi:10.1001/jamaoncol.2017.3372

This cross-sectional survey study quantifies the prevalence of self-reported “job lock” in a sample of full-time employed childhood cancer survivors and their siblings participating in the Childhood Cancer Survivor Study.

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

Abstract Full Text
open access
JAMA Oncol. 2018;4(5):712-716. doi:10.1001/jamaoncol.2017.5604

This ad hoc analysis of data from 2 clinical trials examines factors that may predict complete response in patients with chronic lymphocytic leukemia or small lymphocytic leukemia treated with ibrutinib.

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):717-721. doi:10.1001/jamaoncol.2017.5332

This cohort study assesses whether baseline and early therapy circulating tumor DNA measurements differentiate pseudoprogression from true progression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies.

Research Letter

Association of High Body Mass Index and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection: A Korean Population-Based Cohort Study

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):737-739. doi:10.1001/jamaoncol.2018.0035

This analysis of population-level data examines evidence of the association between body mass index and development of hepatocellular carcinoma among men and women with chronic hepatitis B virus infection.

Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):739-742. doi:10.1001/jamaoncol.2018.0049

This cohort study examines the association of concomitant genetics alterations with response to treatment with epidermal growth factor receptor tyrosine kinase inhibitors among patients with EGFR-mutant advanced non–small cell lung cancer.

Review

Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Review

Abstract Full Text
JAMA Oncol. 2018;4(5):725-734. doi:10.1001/jamaoncol.2017.5305

This review compares the basic features of pediatric and adult chemotherapy regimens for acute lymphoblastic leukemia and lymphoblastic lymphoma, recognizes and describes the challenges of the pediatric regimen, and suggests strategies to facilitate its adoption.

JAMA Oncology Clinical Challenge

A Peculiar Adenocarcinoma

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(5):735-736. doi:10.1001/jamaoncol.2017.3989

A man in his 60s presented with a 1-year history of a mild, dry cough; a chest radiograph revealed a 10 × 9-cm lobulated left lower lobe mass. What is your diagnosis?

Viewpoint

The US Food and Drug Administration’s Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?

Abstract Full Text
JAMA Oncol. 2018;4(5):623-624. doi:10.1001/jamaoncol.2017.5697

This Viewpoint examines the data and circumstances behind the US Food and Drug Administration approval of sunitinib as adjuvant treatment for patients with resected renal cell carcinoma who are at a high risk of relapse.

Using the Cancer Moonshot to Conquer Cancer Disparities: A Model for Action

Abstract Full Text
JAMA Oncol. 2018;4(5):624-625. doi:10.1001/jamaoncol.2017.5694

This Viewpoint describes how the Cancer Moonshot Initiative provides an opportunity to address cancer disparities and inequities and ways to ensure that its goals are achieved.

Mantle Cell Lymphoma—Time to Dismantle the Treatment Paradox

Abstract Full Text
JAMA Oncol. 2018;4(5):626-627. doi:10.1001/jamaoncol.2017.5685

This Viewpoint provides an overview of the 2 clinical variants of Mantle cell lymphoma and discusses that the aggressive treatment may not be beneficial for the indolent variant.

Editorial

The Value of Behavioral Counseling for Skin Cancer Prevention: Actions We Can Take Now and Guidance for the Future

Abstract Full Text
JAMA Oncol. 2018;4(5):630-632. doi:10.1001/jamaoncol.2018.0469

JAMA Oncology—The Year in Review, 2017

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):632-633. doi:10.1001/jamaoncol.2017.5108
Invited Commentary

Insights Into the Management of Lymph Node–Positive Penile Cancer

Abstract Full Text
JAMA Oncol. 2018;4(5):650-651. doi:10.1001/jamaoncol.2017.5634

Improved JAK Inhibition in Myelofibrosis—The Long Road Ahead

Abstract Full Text
JAMA Oncol. 2018;4(5):659-660. doi:10.1001/jamaoncol.2017.5802

Hepatocellular Carcinoma With Portal Venous Invasion: Radiating New Hope?

Abstract Full Text
JAMA Oncol. 2018;4(5):669-670. doi:10.1001/jamaoncol.2018.0007
JAMA Oncology Patient Page

Lymphedema

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):755. doi:10.1001/jamaoncol.2017.5553

This Patient Page provides information of lymphedema, a condition caused by lymph system blockage or damage.

Cancer Care Chronicles

My Unfortunate Introduction Into the Financial Toxicity of Cancer Care in America—March Forth

Abstract Full Text
JAMA Oncol. 2018;4(5):628-629. doi:10.1001/jamaoncol.2017.4436

This article discusses the benefits of shared decision making and having open discussions about costs in the cancer care debate.

Comment & Response

The Paradigm of Escalation of Commitment in Treatment Decisions Near the End of Life

Abstract Full Text
JAMA Oncol. 2018;4(5):742. doi:10.1001/jamaoncol.2017.0161

The Paradigm of Escalation of Commitment in Treatment Decisions Near the End of Life

Abstract Full Text
JAMA Oncol. 2018;4(5):742. doi:10.1001/jamaoncol.2017.4704

Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors

Abstract Full Text
JAMA Oncol. 2018;4(5):743. doi:10.1001/jamaoncol.2017.3983

Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors

Abstract Full Text
JAMA Oncol. 2018;4(5):743-744. doi:10.1001/jamaoncol.2017.4878

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia

Abstract Full Text
JAMA Oncol. 2018;4(5):744-745. doi:10.1001/jamaoncol.2017.0734

Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors—Reply

Abstract Full Text
JAMA Oncol. 2018;4(5):744. doi:10.1001/jamaoncol.2017.4891

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia—Reply

Abstract Full Text
JAMA Oncol. 2018;4(5):745-746. doi:10.1001/jamaoncol.2017.5100

Trend Analysis on Reoperation After Lumpectomy for Breast Cancer

Abstract Full Text
JAMA Oncol. 2018;4(5):746-747. doi:10.1001/jamaoncol.2017.5227

Trend Analysis on Reoperation After Lumpectomy for Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(5):747. doi:10.1001/jamaoncol.2017.5261

Oregon’s Death With Dignity Act

Abstract Full Text
JAMA Oncol. 2018;4(5):747-748. doi:10.1001/jamaoncol.2017.5302

Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Locally Advanced, Recurrent, and Metastatic Prostate Cancer

Abstract Full Text
JAMA Oncol. 2018;4(5):748-749. doi:10.1001/jamaoncol.2017.0287

Oregon’s Death With Dignity Act—Reply

Abstract Full Text
JAMA Oncol. 2018;4(5):748. doi:10.1001/jamaoncol.2017.5323

Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Locally Advanced, Recurrent, and Metastatic Prostate Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(5):749-750. doi:10.1001/jamaoncol.2017.5340

Questions About Emergency Department Treatment of Patients With Solid Tumors and Hematological Malignant Neoplasms

Abstract Full Text
JAMA Oncol. 2018;4(5):750. doi:10.1001/jamaoncol.2017.5531

Questions About Emergency Department Treatment of Patients With Solid Tumors and Hematological Malignant Neoplasms—Reply

Abstract Full Text
JAMA Oncol. 2018;4(5):750-751. doi:10.1001/jamaoncol.2017.5534
Correction

Data Presentation Error in Results Paragraph of Abstract

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):751. doi:10.1001/jamaoncol.2018.0302
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):617. doi:10.1001/jamaoncol.2017.3222
Peer Reviewers List

JAMA Oncology Peer Reviewers in 2017

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(5):e180204. doi:10.1001/jamaoncol.2018.0204
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(5):605. doi:10.1001/jamaoncol.2017.3221
×